Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02340221
Title A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

estrogen-receptor positive breast cancer

Therapies

Fulvestrant + Taselisib

Fulvestrant

Age Groups: adult senior

Additional content available in CKB BOOST